Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nivolumab + lirilumab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Nivolumab + lirilumab is a combination of two monoclonal antibodies used in cancer immunotherapy. Nivolumab is an immune checkpoint inhibitor that targets the programmed cell death protein 1 (PD-1) receptor on T cells, blocking its interaction with PD-L1 and PD-L2 ligands, thereby enhancing T-cell-mediated anti-tumor responses[3][8]. Lirilumab targets killer-cell immunoglobulin-like receptors (KIRs) on natural killer (NK) cells, blocking inhibitory signals from HLA-C ligands and promoting NK cell activation and tumor cell killing[6]. This combination has been investigated in clinical trials for squamous cell carcinoma of the head and neck, showing enhanced objective response rates compared to nivolumab alone[5]. Nivolumab was developed by Bristol Myers Squibb; lirilumab was developed by Innate Pharma.
- Brand names
- Opdivo
- Other names
- lirilumab and nivolumablirilumab/nivolumabanti-KIR plus anti-PD-1 antibody combination
02
Targets
KIR2DL3PDCD1 (Programmed cell death protein 1 receptor)KIR2DL2 (Killer cell immunoglobulin-like receptor 2DL2)KIR2DL1
Beyond the preview
Go deeper on nivolumab + lirilumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nivolumab + lirilumab.